54730-30-2

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 503-60-6 3,3-dimethyl-allyl chloride 
• 23639-82-9 p-hydroxybenzaldehyde ethylene glycol acetal 
• 870-63-3 prenyl bromide 
• 54730-29-9 4-((2-methylbut-3-en-2-yl)oxy)benzaldehyde 
• 115-18-4 2-methyl-3-buten-2-ol 

Downstream Products

• 74021-58-2 4-methoxymethoxy-3-(3-methyl-but-2-enyl)-benzaldehyde 
• 495412-62-9 3-(3-methylbut-2-enyl)-4-(tetrahydropyran-2-yloxy)benzaldehyde 
• 263902-98-3 4-(hydroxymethyl)-2-(3-methylbut-2-en-1-yl)phenol 
• 1608121-21-6 (Z)-5-(4-hydroxy-3-(3-methylbut-2-en-1-yl)benzylidene)-4-(4-hydroxyphenyl)furan-2(5H)-one 
• 1608121-24-9 (Z)-5-((2,2-dimethylchroman-6-yl)methylene)-4-(4-hydroxyphenyl)furan-2(5H)-one 
• 151135-82-9 (E)-1-<2,4-dihydroxy-3-(3-methyl-2-butenyl)phenyl>-3-<4-hydroxy-3-(3-methyl-2-butenyl)phenyl>-2-propen-1-one 
• 54730-32-4 3-(3-methylbut-2-en-1-yl)-4-((2-methylbut-3-yn-2-yl)oxy)benzaldehyde 
• 1138-41-6 4-hydroxy-3-prenylbenzoic acid 
• 56074-98-7 4-Methoxy-3-(γ,γ-dimethylallyl)benzaldehyde 

Relevant academic research and scientific papers

Flavonoid-triazolyl hybrids as potential anti-hepatitis C virus agents: Synthesis and biological evaluation

A series of flavonoid-triazolyl hybrids were synthesized and evaluated as novel inhibitors of hepatitis C virus (HCV). The results of anti-HCV activity assays showed that most of the synthesized derivatives at a concentration of 100 μg/mL inhibited the ge

Furanone compound and preparation method and application thereof

The invention discloses a furanone compound and a preparation method and application thereof. P-hydroxybenzaldehyde is used as a raw material, condensed with hydantoin and then subjected to alkaline hydrolysis and esterification to obtain a p-hydroxyphenylpyruvate intermediate; p-hydroxy benzaldehyde and halogenated isopentene are subjected to alkylation, and then benzyl protection is performed toobtain a benzaldehyde derivative intermediate; a benzaldehyde derivative intermediate and a phenylpyruvate intermediate are subjected to aldol condensation and intramolecular esterification under thecatalysis of a condensing agent to synthesize novel furanone compounds BL5 and BL10. The furanone derivative has H1N1 virus inhibition activity, and can be used for preparing medicines for treating H1N1 virus infection.

Flavanone derivative as well as preparation method and application thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a flavanone derivative, a pharmaceutical composition of the flavanone derivative serving as an active ingredient, a preparation methods of the flavanone deriv

Butenolide derivative as well as preparation method and application thereof

The invention discloses a butenolide compound as well as a preparation method and an application thereof. The butenolide derivative has the inhibitory activity of protein tyrosine phosphatase 1B (PTP1B), improves insulin resistance of HepG2 cells, generates a remarkable hypoglycemic effect and can be used for preparing a medicine for treating diabetes mellitus.

Concise, stereocontrolled and modular syntheses of the anti-influenza rubrolides R and S

The fungal metabolites rubrolide R and S were synthesized in concise, entirely stereoselective fashion through the combined use of bromine-stereodirected vinylogous aldol condensation (SVAC) and Suzuki cross-coupling. A bioinspired, high-yield conversion

Synthesis method and use of natural product Angusticornin A

The invention discloses a synthesis method and use of a natural product that is Angusticornin A. The structure formula (I) of the natural product is shown in the description. The obtained natural product Angusticornin A has good inhibitory activity agains

Synthetic methods for prenylated chalcones and pyranochalcones

The inventors of the present invention invented a simple and effective way to synthesize compounds 1-9 of natural prenylated chalcones and pyrano chalcones by using Claisen-Schmidt condensation as a main step. In addition, an anti-inflammatory effect of synthetic compounds was evaluated in RAW 264.7 macrophages which were stimulated with a lipopolysaccharide. As a result, chalcone compounds having prenyl groups in a ring A (an acetophenone part) show weak inhibition or no inhibition on the generation of nitrogen oxide while chalcones (5, 6, 8, and 9) having no prenyl groups in the ring A show normal or good activity, and have no cytotoxicity.COPYRIGHT KIPO 2017

Protecting-Group-Free Total Syntheses of Rubrolide R and S

The two marine natural products rubrolide R (1) and S (2) were synthesised in only three linear steps starting from commercially available tetronic acid without using protecting-group chemistry. Key steps in the syntheses were the Pd-catalysed Suzuki–Miya

A Monooxygenase from Boreostereum vibrans Catalyzes Oxidative Decarboxylation in a Divergent Vibralactone Biosynthesis Pathway

The oxidative decarboxylation of prenyl 4-hydroxybenzoate to prenylhydroquinone has been frequently proposed for the biosynthesis of prenylated (hydro)quinone derivates (sometimes meroterpenoids), yet no corresponding genes or enzymes have so far been reported. A FAD-binding monooxygenase (VibMO1) was identified that converts prenyl 4-hydroxybenzoate into prenylhydroquinone and is likely involved in the biosynthesis of vibralactones and other meroterpenoids in the basidiomycete Boreostereum vibrans. Feeding of 3-allyl-4-hydroxybenzylalcohol, an analogue of the vibralactone pathway intermediate 3-prenyl-4-hydroxybenzylalcohol, generated 20 analogues with different scaffolds. This demonstrated divergent pathways to skeletally distinct compounds initiating from a single precursor, thus providing the first insight into a novel biosynthetic pathway for 3-substituted γ-butyrolactones from a shikimate origin.

Synthesis and pharmacological properties of naturally occurring prenylated and pyranochalcones as potent anti-inflammatory agents

An efficient approach has been developed for the synthesis of naturally occurring prenylated chalcones viz. kanzonol C (1), stipulin (2), crotaorixin (3), medicagenin (4), licoagrochalcone A (5) and abyssinone D (6) along with the pyranochalcones paratocarpin C (7), anthyllisone (8) and 3-O-methylabyssinone A (9). The key step of the synthesis is a Claisen-Schmidt condensation. Subsequently, their anti-inflammatory effects were investigated in lipopolysaccharides (LPSs)-induced RAW-264.7 macrophages. Of the synthesized chalcones, compounds 5 (IC50 = 10.41 μmol/L), 6 (IC50 = 9.65 μmol/L) and 8 (IC50 = 15.34 μmol/L) show remarkable activity with no cytotoxicity. Compound 9 (IC50 = 4.5 μmol/L) exhibits maximum (83.6%) nitric oxide (NO) inhibition, but shows slight cytotoxicity. The results reveal that the chalcones bearing the prenyl group at 3- and/or 5-position on ring A (acetophenone moiety), i.e., 1-4 and 7 show weak, or no inhibition activity, whereas chalcones having the prenyl group only on ring B (aldehyde part), i.e., 5, 6 and 8 show significant activity on the production of inflammatory mediated NO with no cytotoxicity.